Free Trial

Anixa Biosciences (ANIX) Competitors

Anixa Biosciences logo
$3.08 -0.07 (-2.22%)
Closing price 03/27/2025 04:00 PM Eastern
Extended Trading
$3.13 +0.05 (+1.75%)
As of 03/27/2025 07:58 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

ANIX vs. ALLO, ARCT, RVNC, ABVX, HUMA, AURA, RAPP, RNAC, TSHA, and ATXS

Should you be buying Anixa Biosciences stock or one of its competitors? The main competitors of Anixa Biosciences include Allogene Therapeutics (ALLO), Arcturus Therapeutics (ARCT), Revance Therapeutics (RVNC), ABIVAX Société Anonyme (ABVX), Humacyte (HUMA), Aura Biosciences (AURA), Rapport Therapeutics (RAPP), Cartesian Therapeutics (RNAC), Taysha Gene Therapies (TSHA), and Astria Therapeutics (ATXS). These companies are all part of the "pharmaceutical products" industry.

Anixa Biosciences vs.

Allogene Therapeutics (NASDAQ:ALLO) and Anixa Biosciences (NASDAQ:ANIX) are both small-cap medical companies, but which is the better investment? We will contrast the two businesses based on the strength of their dividends, community ranking, media sentiment, earnings, institutional ownership, analyst recommendations, risk, valuation and profitability.

In the previous week, Anixa Biosciences had 15 more articles in the media than Allogene Therapeutics. MarketBeat recorded 22 mentions for Anixa Biosciences and 7 mentions for Allogene Therapeutics. Allogene Therapeutics' average media sentiment score of 1.13 beat Anixa Biosciences' score of 0.17 indicating that Allogene Therapeutics is being referred to more favorably in the media.

Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment
Allogene Therapeutics
2 Very Positive mention(s)
0 Positive mention(s)
1 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Positive
Anixa Biosciences
1 Very Positive mention(s)
4 Positive mention(s)
8 Neutral mention(s)
0 Negative mention(s)
2 Very Negative mention(s)
Neutral

Allogene Therapeutics currently has a consensus price target of $9.29, indicating a potential upside of 495.44%. Anixa Biosciences has a consensus price target of $9.00, indicating a potential upside of 192.21%. Given Allogene Therapeutics' higher probable upside, equities research analysts clearly believe Allogene Therapeutics is more favorable than Anixa Biosciences.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Allogene Therapeutics
0 Sell rating(s)
1 Hold rating(s)
9 Buy rating(s)
0 Strong Buy rating(s)
2.90
Anixa Biosciences
0 Sell rating(s)
0 Hold rating(s)
3 Buy rating(s)
1 Strong Buy rating(s)
3.25

Allogene Therapeutics received 253 more outperform votes than Anixa Biosciences when rated by MarketBeat users. However, 75.61% of users gave Anixa Biosciences an outperform vote while only 65.89% of users gave Allogene Therapeutics an outperform vote.

CompanyUnderperformOutperform
Allogene TherapeuticsOutperform Votes
284
65.89%
Underperform Votes
147
34.11%
Anixa BiosciencesOutperform Votes
31
75.61%
Underperform Votes
10
24.39%

Anixa Biosciences has higher revenue and earnings than Allogene Therapeutics. Anixa Biosciences is trading at a lower price-to-earnings ratio than Allogene Therapeutics, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Allogene Therapeutics$22K15,406.06-$327.27M-$1.33-1.17
Anixa Biosciences$210K472.22-$12.55M-$0.39-7.90

83.6% of Allogene Therapeutics shares are held by institutional investors. Comparatively, 29.1% of Anixa Biosciences shares are held by institutional investors. 24.3% of Allogene Therapeutics shares are held by insiders. Comparatively, 25.3% of Anixa Biosciences shares are held by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock will outperform the market over the long term.

Allogene Therapeutics has a beta of 1.02, meaning that its share price is 2% more volatile than the S&P 500. Comparatively, Anixa Biosciences has a beta of 0.86, meaning that its share price is 14% less volatile than the S&P 500.

Allogene Therapeutics' return on equity of -52.13% beat Anixa Biosciences' return on equity.

Company Net Margins Return on Equity Return on Assets
Allogene TherapeuticsN/A -52.13% -41.29%
Anixa Biosciences N/A -58.55%-53.29%

Summary

Allogene Therapeutics beats Anixa Biosciences on 10 of the 18 factors compared between the two stocks.

Remove Ads
Get Anixa Biosciences News Delivered to You Automatically

Sign up to receive the latest news and ratings for ANIX and its competitors with MarketBeat's FREE daily newsletter.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Skip Chart

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Skip Chart

ANIX vs. The Competition

MetricAnixa BiosciencesPharmaceutical IndustryMedical SectorNASDAQ Exchange
Market Cap$99.17M$6.91B$5.64B$8.06B
Dividend YieldN/A2.73%4.57%4.01%
P/E Ratio-7.907.2023.1419.03
Price / Sales472.22226.01384.1193.17
Price / CashN/A65.6738.1634.64
Price / Book5.226.476.954.33
Net Income-$12.55M$141.90M$3.20B$247.06M
7 Day Performance-2.53%-3.20%-2.28%-0.37%
1 Month Performance-2.22%-5.64%2.88%-3.85%
1 Year Performance-1.28%-7.47%10.87%1.27%

Anixa Biosciences Competitors List

CompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)
ANIX
Anixa Biosciences
3.1823 of 5 stars
$3.08
-2.2%
$9.00
+192.2%
-4.6%$99.17M$210,000.00-7.905Analyst Forecast
Analyst Revision
News Coverage
Gap Up
ALLO
Allogene Therapeutics
3.2377 of 5 stars
$1.85
-4.6%
$9.40
+408.1%
-65.0%$387.89M$22,000.00-1.19310Positive News
ARCT
Arcturus Therapeutics
2.7645 of 5 stars
$14.16
+0.6%
$59.20
+318.1%
-63.5%$384.02M$138.39M-6.38180Positive News
RVNC
Revance Therapeutics
2.0128 of 5 stars
$3.65
flat
$8.39
+129.7%
N/A$381.02M$234.04M-1.89500Analyst Forecast
ABVX
ABIVAX Société Anonyme
2.0608 of 5 stars
$6.00
+1.0%
$38.67
+544.4%
-53.9%$380.30MN/A0.0061Analyst Revision
News Coverage
Gap Down
High Trading Volume
HUMA
Humacyte
2.1569 of 5 stars
$3.01
-1.0%
$13.71
+355.6%
-35.2%$378.84M$1.57M-2.25150Analyst Forecast
News Coverage
AURA
Aura Biosciences
2.1682 of 5 stars
$7.54
+2.6%
$23.00
+205.0%
-22.9%$376.63MN/A-4.3650Earnings Report
Analyst Revision
News Coverage
High Trading Volume
RAPP
Rapport Therapeutics
1.7376 of 5 stars
$10.18
-3.1%
$35.00
+243.8%
N/A$371.53MN/A-0.74N/AShort Interest ↑
RNAC
Cartesian Therapeutics
2.4042 of 5 stars
$14.44
-8.6%
$42.14
+191.8%
-27.5%$366.99M$47.94M-0.2764Positive News
TSHA
Taysha Gene Therapies
2.761 of 5 stars
$1.79
+4.1%
$6.63
+270.1%
-40.7%$366.95M$8.33M2.84180Positive News
ATXS
Astria Therapeutics
1.7843 of 5 stars
$6.48
+0.5%
$26.67
+311.5%
-55.4%$365.69MN/A-3.1030Positive News
Remove Ads

Related Companies and Tools


This page (NASDAQ:ANIX) was last updated on 3/28/2025 by MarketBeat.com Staff
From Our Partners